We narrowed to 59 results for: ina

#52962-LV

Ready-to-use Lentiviral Prep particles produced from lentiCas9-Blast (#52962). In addition to the viral particles, you will also receive purified lentiCas9-Blast plasmid DNA. Lentiviral particles carrying Cas9 and blasticidin resistance. This virus is used to make stable cell lines expressing Cas9.

Feng Zhang

Sanjana et al Nat Methods. 2014 Aug;11(8):783-4. doi:

July 14, 2016

Academic Institutions and Nonprofits only

#24593-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-pgk-Cre (#24593). In addition to the viral particles, you will also receive purified AAV-pgk-Cre plasmid DNA. Cre expression under the PGK promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons.

Patrick Aebischer

July 24, 2017

Academic Institutions and Nonprofits only

#84445-AAV5

Ready-to-use AAV5 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] (#84445). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] plasmid DNA. CAG-driven, Cre-dependent Jaws-GFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Oct. 10, 2018

Academic Institutions and Nonprofits only

#87306-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Li Zhang

Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

July 22, 2020

Academic Institutions and Nonprofits only

#65014-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hsyn-Jaws-KGC-GFP-ER2 (#65014). In addition to the viral particles, you will also receive purified pAAV-hsyn-Jaws-KGC-GFP-ER2 plasmid DNA. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Aug. 14, 2017

Academic Institutions and Nonprofits only

#84445-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] (#84445). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] plasmid DNA. CAG-drive, Cre-dependent Jaws-GFP for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Oct. 12, 2017

Academic Institutions and Nonprofits only

#131004-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-GCaMP 6m-p2A-ChRmine-Kv2.1-WPRE (#131004). In addition to the viral particles, you will also receive purified pAAV-hSyn-GCaMP 6m-p2A-ChRmine-Kv2.1-WPRE plasmid DNA. hSyn-driven expression of calcium sensor GCaMP6m and bicistronic ChRmine (red-shifted channelrhodopsin). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

June 4, 2020

Academic Institutions and Nonprofits only

#65014-AAV5

Ready-to-use AAV5 particles produced from pAAV-hsyn-Jaws-KGC-GFP-ER2 (#65014). In addition to the viral particles, you will also receive purified pAAV-hsyn-Jaws-KGC-GFP-ER2 plasmid DNA. hSyn-driven Jaws-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Feb. 7, 2018

Academic Institutions and Nonprofits only

#87306-AAV1

Ready-to-use AAV1 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

Li Zhang

Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

April 18, 2019

Academic Institutions and Nonprofits only

#124364-AAV2

Ready-to-use AAV2 particles produced from pAAV-FLEX-DTR-GFP (#124364). In addition to the viral particles, you will also receive purified pAAV-FLEX-DTR-GFP plasmid DNA. CBA-driven, Cre-dependent expression of DTR-GFP. These AAV preparations are suitable purity for injection into animals.

Eiman Azim, Thomas Jessell

Azim et al Nature. 2014 Apr 17;508(7496):357-63. do

June 16, 2020

Academic Institutions and Nonprofits only

#130995-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-ChRmine-mScarlet-Kv2.1-WPRE (#130995). In addition to the viral particles, you will also receive purified pAAV-hSyn-ChRmine-mScarlet-Kv2.1-WPRE plasmid DNA. hSyn-driven, soma-targeted ChRmine-mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Jan. 6, 2022

Academic Institutions and Nonprofits only

#196410-AAV5

Ready-to-use AAV5 particles produced from AAV-GfaABC1D-Cre-4x6T (#196410). In addition to the viral particles, you will also receive purified AAV-GfaABC1D-Cre-4x6T plasmid DNA. GfaABC1D driven expression of Cre recombinase in astrocytes. These AAV preparations are suitable purity for injection into animals.

Stanley Thomas Carmichael

Gleichman et al Nat Commun. 2023 Nov 16;14(1):7426. doi:

Sept. 27, 2024

Academic Institutions and Nonprofits only

#51669-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV phSyn1(S)-FlpO-bGHpA (#51669). In addition to the viral particles, you will also receive purified AAV phSyn1(S)-FlpO-bGHpA plasmid DNA. hSyn-driven FlpO expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

Oct. 28, 2021

Academic Institutions and Nonprofits only

#130998-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO-ChRmine-mScarlet-WPRE (#130998). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-ChRmine-mScarlet-WPRE plasmid DNA. Ef1a-driven, Cre-dependent expression of ChRmine-mScarlet. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

March 18, 2024

Academic Institutions and Nonprofits only

#130991-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-ChRmine-mScarlet-Kv2.1-WPRE (#130991). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-ChRmine-mScarlet-Kv2.1-WPRE plasmid DNA. CamKIIa-driven, soma-targeted ChRmine-mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Jan. 6, 2022

Academic Institutions and Nonprofits only

#65014-AAV8

Ready-to-use AAV8 particles produced from pAAV-hsyn-Jaws-KGC-GFP-ER2 (#65014). In addition to the viral particles, you will also receive purified pAAV-hsyn-Jaws-KGC-GFP-ER2 plasmid DNA. hSyn-driven Jaws-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Oct. 13, 2017

Academic Institutions and Nonprofits only

#84445-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] (#84445). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] plasmid DNA. CAG-driven, Cre-dependent Jaws-GFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Aug. 24, 2020

Academic Institutions and Nonprofits only

#75033-AAV1

Ready-to-use AAV1 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

March 27, 2019

Academic Institutions and Nonprofits only

#87306-AAV9

Ready-to-use AAV9 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

Li Zhang

Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

Jan. 26, 2021

Academic Institutions and Nonprofits only

#84446-AAV5

Ready-to-use AAV5 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (#84446). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] plasmid DNA. CAG-driven, Cre-dependent expression of Jaws-KGC-tdTomato-ER2 for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

June 26, 2024

Academic Institutions and Nonprofits only